Universal Vectors for the Therapy of Cancer
Universal Vectors for the Therapy of Cancer
批准号:
6712866
负责人:
MANUEL L PENICHET
金额:
$14.51万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2006-03-31
关键词:
SCID mouseaminohydrolasesavidinbeta galactosidasebiotincarcinomachimeric proteinscytokine receptorsendoribonucleasesfluorescence microscopygene therapygenetic manipulationgreen fluorescent proteinshaptenshypoxanthine phosphoribosyltransferaseinterleukin 2mycophenolic acidneoplasm /cancer therapynonhuman therapy evaluationreceptor bindingreceptor mediated endocytosisrecombinant proteinstransfection /expression vectortransferrin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (provided by Applicant) My immediate career goal is continue my
research in the fields of cancer research focusing mainly in the development
of new drugs for cancer therapy. To achieve this goal I propose to develop
universal delivery systems that can be used to deliver DNA or cytotoxic
molecules to tumor cells expressing on their surface the interleukin-2 (IL-2)
or transferrin (Tf) receptor (IL-2R or Tf-R). The delivery system will be
antibody fusion proteins that either have the ligand (e.g., IL-2 or Tf)
covalently associated or have a variable region that recognizes a growth
factor receptor (e.g., anti-TfR). The antibody fusion proteins containing IL-
2 or Tf will be specific for the hapten dansyl (DNS) and will be used for the
delivery of dansylated agents. The anti-TfR antibody will be covalently fused
to avidin and will be used for the delivery of biotinylated agents. To
produce and characterize the delivery vehicles I propose the following
specific aims: 1. Produce the recombinant antibody fusion proteins to be used
as universal delivery vehicles; 2. Evaluate the ability of the Ab fusion
proteins to deliver proteins or DNA to cells growing in vitro; 3. Determine
the properties of the Ab fusion proteins in vivo and their ability to target
and eliminate tumors in animal models. I anticipate that the vector systems
will provide powerful tools for treating a wide variety of important
malignancies. The universal vectors will make it easier to treat tumors with
multiple anti-cancer agents and will facilitate the rapid evaluation of
potential new therapeutic agents. Although initial principles will be
established using IL-2R and/or TfR as targets, future universal vectors can
target other tumor associated molecules. Having been trained as an
M.D./Ph.D., I have a strong grounding in both basic and clinical science. The
training that I will receive during the time of this grant will enhance both
my research skills and my facility with English. This additional training is
necessary if I am to assume an independent position doing research at a major
university. UCLA provides an excellent, supportive environment for the
proposed research. There is a large faculty with expertise in virtually every
discipline. Excellent seminar series and technical training sessions are
available. The University is committed to my career development and will
provide resources without requiring any teaching or clinical activities. The
training period will also allow me to attend national and international
meetings, both expanding my expertise and my network of collaborators and
colleagues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
-
批准号:9054822
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2015
-
负责人:MANUEL L PENICHET
-
依托单位:
(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma
-
批准号:8870884
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2015
-
负责人:MANUEL L PENICHET
-
依托单位:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
-
批准号:9331321
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2014
-
负责人:MANUEL L PENICHET
-
依托单位:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
-
批准号:8915101
-
项目类别:
-
资助金额:$44.51万
-
财政年份:2014
-
负责人:MANUEL L PENICHET
-
依托单位:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
-
批准号:8759266
-
项目类别:
-
资助金额:$36.96万
-
财政年份:2014
-
负责人:MANUEL L PENICHET
-
依托单位:
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy
-
批准号:9114545
-
项目类别:
-
资助金额:$55.66万
-
财政年份:2014
-
负责人:MANUEL L PENICHET
-
依托单位:
Development of an anti-PSA IgE to treat prostate cancer
-
批准号:7608973
-
项目类别:
-
资助金额:$15.89万
-
财政年份:2009
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7321093
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7615306
-
项目类别:
-
资助金额:$8.62万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:6999287
-
项目类别:
-
资助金额:$30.93万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7243585
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7533462
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:6864951
-
项目类别:
-
资助金额:$25.24万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7148065
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma
-
批准号:7338100
-
项目类别:
-
资助金额:$8.4万
-
财政年份:2004
-
负责人:MANUEL L PENICHET
-
依托单位:
Universal Vectors for the Therapy of Cancer
-
批准号:6855055
-
项目类别:
-
资助金额:$14.79万
-
财政年份:2001
-
负责人:MANUEL L PENICHET
-
依托单位:
Universal Vectors for the Therapy of Cancer
-
批准号:6326360
-
项目类别:
-
资助金额:$11.04万
-
财政年份:2001
-
负责人:MANUEL L PENICHET
-
依托单位:
Universal Vectors for the Therapy of Cancer
-
批准号:6633761
-
项目类别:
-
资助金额:$11.55万
-
财政年份:2001
-
负责人:MANUEL L PENICHET
-
依托单位:
Universal Vectors for the Therapy of Cancer
-
批准号:6514609
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2001
-
负责人:MANUEL L PENICHET
-
依托单位:
海外基金